Forma Therapeutics Holdings, Inc. (FMTX)
| Market Cap | 301.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -181.16M |
| Shares Out | 50.31M |
| EPS (ttm) | -3.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,922 |
| Open | 5.94 |
| Previous Close | 5.85 |
| Day's Range | 5.60 - 6.16 |
| 52-Week Range | 5.60 - 31.39 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 47.65 (+694.2%) |
| Earnings Date | May 6, 2022 |
About FMTX
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for FMTX stock is "Buy." The 12-month stock price forecast is 47.65, which is an increase of 694.17% from the latest price.
News
Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
4 Biotechs That Were Winners at ASH
Big pharma companies and small biotechs alike emerged from the key American Society of Hematology conference as big winners.
Can Forma Therapeutics Holdings, Inc. (FMTX) Climb 277% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Forma Therapeutics Holdings, Inc. (FMTX) points to a 277.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong...
Forma Therapeutics (FMTX) Sees Hammer Chart Pattern: Time to Buy?
Forma Therapeutics (FMTX) has been struggling lately, but the selling pressure may be coming to an end soon.
Forma Therapeutics' Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma's Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
Forma's (FMTX) Etavopivat Proves Safety Profile in SCD Study
Forma's (FMTX) investigational PKR activator, etavopivat significantly improves anemia and red blood cell health in patients with sickle cell disease.
Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics' Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Appoints Acclaimed Global Sickle Cell Disease Leader, Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
How Much Upside is Left in Forma Therapeutics Holdings, Inc. (FMTX)? Wall Street Analysts Think 185%
The average of price targets set by Wall Street analysts indicates a potential upside of 184.6% in Forma Therapeutics Holdings, Inc. (FMTX). While the effectiveness of this highly sought-after metric is...
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
Forma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing P...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic...
Forma Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Participate in Upcoming Investor Conferences.
Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease. Data were presented at the Annual European Hematology Ass...